facebook
twitter
rss
account
search
search
 

FDA approves generic Requip tablets

May 12, 2008 at 10:14 AM   |   Comments

WASHINGTON, May 12 (UPI) -- The U.S. Food and Drug Administration has approved the first generic versions of a drug designed for the treatment of restless legs syndrome.

The FDA said it approved Requip (ropinirole hydrochloride) in dosages of 0.25 milligrams, 0.5 milligrams, 1 milligram, 2 milligrams, 3 milligrams and 4 milligrams.

The marketing approval went to Roxane Laboratories Inc., Teva Pharmaceuticals USA, Par Pharmaceuticals Inc. and Mylan Pharmaceuticals Inc.

While Requip is also FDA-approved to treat symptoms of Parkinson's disease, the generic products aren't approved for that purpose because that is protected by patent. However, the FDA said the patent expires this month, at which time manufacturers of the generic drugs may seek approval for that use.

© 2008 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Android phones to join iPhone in saying no to the police Android phones to join iPhone in saying no to the police
2
Latest Ebola outbreak spreading much faster than in the past Latest Ebola outbreak spreading much faster than in the past
3
Physicists teleport photon over 15 miles Physicists teleport photon over 15 miles
4
Shellfish-inspired waterproof glue could help repair ships Shellfish-inspired waterproof glue could help repair ships
5
Pennsylvania officials issue $4.15 million fine to fracking company Pennsylvania officials issue $4.15 million fine to fracking company
Trending News
Video
x
Feedback